Salute e Benessere

Sandoz reports third-quarter and nine-month 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics growth acceleration driven by EuropeThird-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)Net sales growth guidance increased to high-single digit in...
Nasdaq GlobeNewswire
30/10/2024

Avance Clinical CEO and Asia Director Sign MOUs with Key Clinical Trial Sites in…

Avance Clinical, a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical research services, is proud to announce the signing of three significant Memorandums of Understanding (MOUs) with key Korean clinical sites during KoNECT 2024 conference.Avance Clinical CEO Yvonne Lungershausen and Asia Regional Director Jessica Han, attended the KoNECT conference, and the three clinical sites to sign these partnerships, marking an important...
Nasdaq GlobeNewswire
30/10/2024

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and…

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen's deep expertise in Alzheimer's, rare, and immunological diseases. CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct.29, 2024(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for...
Nasdaq GlobeNewswire
29/10/2024

Endo Announces Successful Term Loan Repricing

Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements including, but not limited to, interest expense savings and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may,"…
PR Newswire
29/10/2024

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior…

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies 1-3 Patients on Scemblix also had fewer dose reductions and half the rate of adverse reactions leading to treatment discontinuation 1-3 Nearly 50% of CML patients do not meet efficacy milestones (MMR) with current SoC and...
Nasdaq GlobeNewswire
29/10/2024

SKF divests non-core aerospace operation for USD 220 million

"I'm pleased that we have been able to deliver on our prior promises and successfully reached an agreement to divest this successful but non-core business at accretive multiples. With a new owner, I'm confident that Hanover will continue to provide customers with top quality solutions. Aerospace will remain one of our largest customer industries and we will continue to invest and strengthen our position in core Aerospace segments", says Rickard Gustafson, President and CEO. "I'm…
PR Newswire
29/10/2024

NTG Nordic Transport Group publishes interim report for Q3 2024

Company announcement no. 9 – 24 29 October 2024 NTG Nordic Transport Group publishes interim report for Q3 2024The interim report for Q3 2024 is enclosed.In connection with publication of the results for Q3 2024, a conference call will be hosted on 30 October 2024 at 10:00 AM CET.The conference call will be held in English and can be followed live via NTG's website ; investor.ntg.com. Additional information For additional information, please contact: Investor relations...
Nasdaq GlobeNewswire
29/10/2024

LILYSILK Continues Partnership with National Breast Cancer Foundation for Breast…

In March 2024, LILYSILK introduced the Caring Collection in collaboration with NBCF. The collection features silk items such as Hope's Comfort Pillowcase, Eternal Hope Scrunchie, Hopeful Dreams Sleep Eye Mask, and The Hope's Embrace Sleep Set. Each item reflects LILYSILK's dedication to comfort and support for breast cancer patients. Packaged with a pink ribbon-themed seal and messages of gratitude, the collection symbolizes the company's commitment to the fight against breast cancer and its…
PR Newswire
29/10/2024

QuantalX Introduces a Breakthrough in the Diagnosis and Classification of…

Delphi-MD's cutting-edge, direct electrophysiological imaging technology provides real-time insights into brain network function. The system identifies specific physiological changes in brain networks, particularly in the occipital networks, occurring in the early stages of Parkinson's disease. Delphi-MD enables the identification of patients with rapid disease progression, allowing for early intervention and personalized treatment, marking a first in neurological clinical care and potentially…
PR Newswire
29/10/2024

415 Capital Announces €150 Million Second Fund and Key Appointments to…

The fund has already made investments in two clinical-stage cardiovascular companies, with additional transactions expected to be announced soon. The fund has already made investments in two clinical-stage cardiovascular companies, with additional transactions expected to be announced soon. "We are incredibly grateful for the trust our limited partners continue to place in us. Their support highlights the significant clinical impact and value of our portfolio,"said Frederik…
PR Newswire
29/10/2024

Contract Win

DXS INTERNATIONAL PLC(AQSE: DXSP)ExpectCare First Commercial Contract The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its first NHS commercial contract for its leading-edge AI ExpertCare Clinical Decision Support (CDS) solution. This unique digital solution “automates” the gathering of all “relevant” patient and NICE treatment...
Nasdaq GlobeNewswire
29/10/2024

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

BiogenInc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, M.D., M.P.H., Head of Development at Biogen.“At Biogen, scientific and medical leadership is the foundation for everything we do, and this is why we believe Dan will be a perfect fit to lead our Medical Affairs organization going forward,” said Priya Singhal, M.D., M.P.H., Head of Development at...
Nasdaq GlobeNewswire
29/10/2024

Ardena Expands Bioanalytical Services in Europe

The new 3,000+ sqft lab in Oss, expected to be operational by Q1 2025, will provide advanced analytical testing services for both small and large molecules, employing LC-MS/MS and fluorometric detection assays, along with ELISA-based Gyrolab automated technology platform. Meanwhile, Ardena's investments in Assen focus on expanding its capabilities in immunochemistry, flow cytometry, and qPCR platforms, increasing its LC-MS/MS capacity, and adding new Hamilton automated systems to enhance...
Nasdaq GlobeNewswire
29/10/2024

Updated version of the company's articles of association

The updated Articles of Association of MAXIMA GRUPĖ, UAB are announced. Contact person:Lukas RadžiūnasHead of Corporate Relations and Communications+370 666 21 [email protected] Attachment MXGR_Istatai_registruoti 2024-10-24
Nasdaq GlobeNewswire
29/10/2024

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy…

PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such as gait disturbances, early falls, vertical gaze palsy, rigidity, tremors, and cognitive decline, but it progresses faster and currently has no fundamental treatment. PSP is classified into several types, including PSP-Richardson's syndrome ("PSP-RS") and PSP-parkinsonism ("PSP-P"). Compared to other types of PSP, the PSP-RS type shows a greater accumulation of tau protein and affects larger…
PR Newswire
29/10/2024

Zymeworks Announces Participation in Upcoming Investor Conferences

UBS Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on November 12 in Rancho Palos Verdes, CA.Stifel 2024 Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on November 19 at 4:10 pm Eastern Time (ET) in New York, NY.Jefferies London Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on November 20-21 and a fireside chat on November 20 at 2:30 pm Greenwich...
Nasdaq GlobeNewswire
29/10/2024

Discovery of cancer risk associations for six novel genes

In this study, the scientists analysed three large genetic datasets from individuals of European descent, including 130,991 cancer patients and 733,486 controls. Through a gene-based burden association analysis across 22 different cancer types, they found four novel genes associated with a risk of developing cancer; the pro-apoptotic BIK for prostate cancer, the autophagy involved ATG12 for colorectal cancer, TG for thyroid cancer, and CMTR2 for both lung cancer and cutaneous melanoma. The…
PR Newswire
29/10/2024

Orion Group Interim Report January–September 2024

ORION CORPORATIONINTERIM REPORT 1–9/202429 OCTOBER 2024 at 12:00 EETOrion Group Interim Report January–September 2024Net sales totalled EUR 1,108.0 (January–September 2023: 868.5) million Operating profit was EUR 323.8 (182.0) millionBasic earnings per share were EUR 1.83 (1.01)Cash flow from operating activities per share was EUR 1.46 (0.50)The outlook for 2024 was upgraded during the reporting period on 11 September 2024: Net sales are estimated to be EUR 1,470 million to...
Nasdaq GlobeNewswire
29/10/2024

Regional and Global Experts Convene in Accra, Ghana to Update Cancer Treatment…

The NCCN Harmonized Guidelines™ for Sub-Saharan Africa are free resources for optimizing and standardizing cancer care across the region. They are available at NCCN.org/harmonized or via the Virtual Library of NCCN Guidelines® App. The NCCN Harmonized Guidelines™ for Sub-Saharan Africa are free resources for optimizing and standardizing cancer care across the region. They are available atNCCN.org/harmonizedor via theVirtual Library of NCCN Guidelines ®App. "The Sub-Saharan Africa...
PR Newswire
29/10/2024

MGI Tech and OncoDNA join forces to offer laboratories a streamlined NGS…

Previously limited to one sequencing technology/platform provider, the OncoDEEP® Kit's analysis process now also provides exceptional results and clinical insights, supporting laboratories in performing solid tumor Comprehensive Genomic Profiling using MGI sequencers which utilize the cutting-edge DNBSEQ™ technology. Previously limited to one sequencing technology/platform provider, the OncoDEEP ®Kit's analysis process now also provides exceptional results and clinical insights, supporting...
PR Newswire
29/10/2024

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication…

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age.COPENHAGEN, Denmark, October 29, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN ®mpox/smallpox vaccine in children 2 to 11 years of age.The first children have now been vaccinated in the study, which is currently enrolling in the Democratic Republic of Congo (DRC) with plans also to...
Nasdaq GlobeNewswire
29/10/2024

Idorsia announces financial results for the first nine months of 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. Highlights Net revenue9M 2024 at CHF 53 million. US GAAP operating loss9M 2024 of CHF 154 million andNon-GAAP operating lossof CHF 248 million. Improved Guidancefor 2024, driven by diligent cost control. QUVIVIQ™(daridorexant) total net sales of CHF 39 million in 9M 2024.Commercial...
Nasdaq GlobeNewswire
29/10/2024

Novartis continues strong momentum in Q3 with 10% sales growth, 20% core…

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc 1, +9% USD) with core operating income up +20% (cc, +17% USD)Sales growth driven by continued strong performance fromEntresto(+26% cc),Cosentyx(+28% cc),Kisqali(+43% cc),Kesimpta(+28% cc),Pluvicto(+50% cc) andLeqvio(+119% cc)Core operating income margin 40.1%, +340 basis points (cc), mainly driven by higher net sales Q3 operating income grew +123% (cc, +106% USD); net income…
Nasdaq GlobeNewswire
29/10/2024

The world's first 100% “fiber-to-fiber” biorecycled clothing unveiled by…

For the first time, a piece of clothing is made entirely from textile waste – no bottles, no packaging, no virgin plastic. 100% biorecycled fibers.By developing and industrializing CARBIOS' enzymatic depolymerization technology to achieve 100% “fiber-to-fiber” recycling, the consortium collectively advances the textile industry's shift towards a circular economy Clermont-Ferrand (France), 29 October 2024 (06.45am CET). CARBIOS,(Euronext Growth Paris : ALCRB), a pioneer in the...
Nasdaq GlobeNewswire
29/10/2024
Altri  Comunicati